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ABSTRACT 
The microRNA MIR211 is an important regulator of melanoma tumor cell behavior. Previous 
studies suggested that in certain tumors, MIR211 acted as a tumor suppressor while in others it 
behaved as an oncogenic regulator. When MIR211 is expressed in BRAFV600E-mutant A375 
melanoma cells in mouse xenografts, it promotes aggressive tumor growth accompanied by 
increased cellular proliferation and angiogenesis. We demonstrate that MIR211 is transferred to 
adjacent cells in the tumor micro-environment via exosomes.  Cross-species genome-wide 
transcriptomic analysis showed that human tumor-derived MIR211 interacts with the mouse 
transcriptome in the tumor microenvironment, and activates ERK5 signaling in human tumor 
cells via the modulation of a feedback loop. Human miR211 directly inhibits human DUSP6 
protein phosphatase at the post-transcriptional level. We provide support for the hypothesis that 
DUSP6 inhibition conferred resistance of the human tumor cells to the BRAF inhibitor 
vemurafenib and to the MEK inhibitor cobimetinib, with associated increases in ERK5 
phosphorylation. These findings are consistent with a model in which MIR211 regulates 
melanoma tumor proliferation and BRAF inhibitor resistance by inducing ERK5 signaling within 
the complex tumor microenvironment. We propose that the MIR211-ERK5 axis represents an 
important and sensitive regulatory arm in melanoma with potential theranostic applications. 
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INTRODUCTION 
Malignant melanoma has a high mortality burden if not detected early(1,2). The 
histopathological differentiation of benign pigmented lesions (melanocytic and Spitz nevi) and 
malignant melanoma often presents a diagnostic challenge, driving recent efforts to develop 
novel biomarkers(3,4). Moreover, there continues to be a need to identify molecular master 
regulators and checkpoints to target with novel drugs. Over the past decade, micro-(mi)RNAs 
have emerged as promising diagnostic, therapeutic, and theranostic candidates due to their 
emerging roles in melanoma hallmarks including proliferation, migration, apoptosis, immune 
responses, and in shaping the tumor niche(4,5).  
miRNAs are noncoding 21-23 nucleotide molecules that mostly bind to mRNA 3’UTRs to 
degrade their target and inhibit protein translation(6). miRNAs are critical regulators of tumor 
growth, invasion, angiogenesis, and immune evasion through their control of target gene 
expression(7,8), not least in melanoma(9-14). We discovered a significant role for MIR211 in 
melanocyte and melanoma pathobiology(15,16), with subsequent studies confirming MIR211 as 
a critical regulatory molecule in melanoma(17-22). 
We previously showed that MIR211 is highly expressed in primary melanocytes; expression is 
low or absent in 70% of melanomas, and that expression is reduced in melanotic and amelanotic 
melanoma cell lines(15). Others have reported decreased MIR211 expression in clinical 
melanoma samples (23,24), driving efforts to use MIR211 as a clinical diagnostic test to 
discriminate melanomas from benign nevi(25). We also showed that MIR211 overexpression 
increases mitochondrial respiration in amelanotic melanoma cells by inhibiting pyruvate 
dehydrogenase kinase 4 (PDK4), thereby inhibiting melanoma cell survival and invasion(16).  
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Despite a body of data suggesting a tumor suppressor role for MIR211, Guar et al.(26) reported 
that MIR211 is overexpressed in a majority (6/8) of melanoma lines in the NCI-60 cancer cell 
line panel. MIR211 was also overexpressed in 9/29 melanomas previously analyzed by us(15). 
Recent studies suggest that: (i) MIR211 is transported via melanosomes to the tumor 
microenvironment to activate MAPK signaling and thus to promote melanoma growth(11); (ii) 
MIR211 expression and the melanin biosynthetic pathways are induced by vemurafenib (a 
BRAF inhibitor) treatment and to contribute to vemurafenib resistance(27); and (iii) MIR211 
contributes to BRAF inhibitor resistance in melanoma via MAPK signaling(28). Therefore, 
although MIR211 clearly participates in melanomagenesis, there is considerable complexity 
(tumor-promoter or suppressor) in its mechanisms of action that requires further clarification. 
Here we interrogated the molecular action of MIR211 in vivo. MIR211 overexpression in 
BRAFV600E-mutant A375 melanoma cells promoted aggressive xenografted tumor growth, 
accompanied by cell proliferation and angiogenesis, without marked disruption of the glycolysis 
or tricarboxylic (TCA) pathways, suggesting that MIR211 drives cancer via at least one other 
pathway independent of PDK4. Interrogation of xenograft RNA-seq data revealed activation of 
the ERK5 pathway, which is negatively regulated by the putative MIR211 target gene products 
BIRC2 and DUSP family members. These genes were confirmed as direct MIR211 targets by 
RNA immunopurification with anti-Argonaute-2 antibodies and RNA-seq (RIP-seq) and target 
cleavage assays. Finally, MIR211 conferred resistance to the BRAF inhibitor vemurafenib and 
MEK inhibitor cobimetinib, with corresponding increases in ERK5 phosphorylation. Taken 
together, these observations are consistent with a model in which MIR211 modulates melanoma 
tumor proliferation and resistance to drugs that target the BRAF pathway by inducing signal 
transduction through the ERK5 pathway. 
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MATERIAL AND METHODS 
Cell culture 
Melanoma cell lines, A375 (RRID:CVCL_0132) and SKMEL28 (RRID:CVCL_0526) were 
obtained from the ATCC (American Type Culture Collection, Manassas, VA). LOX-IMV1 
(RRID:CVCL_1381) was purchased from the National Cancer Institute (NCI). 501 Mel and 
A375 derived vemurafenib resistant cell lines(27), A375-P1, A375-P2, A375-C2, and A375-C3, 
were generously provided by Dr. Laura Poliseno at the Institute of Clinical Physiology (Pisa, 
Italy). All cells were grown in complete Tu medium as previously described(29). For 
vemurafenib resistant cells, 2 uM of vemurafenib (PLX4032, Selleckchem, Houston, TX) was 
added. The cells were grown in a humidified incubator at 37°C, 5% CO2. 
Immunohistochemistry 
Formalin-fixed paraffin embedded tissues were stained with routine H&E or used for 
immunohistochemistry. The slides were placed on the Leica Bond RX and stained using primary 
antibody. Heat retrieval was utilized using epitope retrieval solution 1 (Citrate buffer pH6) for 20 
minutes. Antibody was incubated at room temperature for 1hr and was visualized by using 
Leica’s Bond Polymer Refine detection kit (DS9800). Slides were counterstained with 
hematoxylin from the kit then slides were dehydrated and coverslipped. The following primary 
antibodies were used: anti-Ki67 (Thermo Fisher Scientific, Waltham, MA; MA5–14520; 1:100), 
anti-CD31 (Dianova, Barcelona, Spain; Clone SZ31 P/N DIA-310; 1:25), and anti-PDK4 
(LSBio, Seattle, WA; LS-B3459; 1:200). For visualizing CD31, Leica’s Bond Polymer Refine 
Red detection kit (DS9390) and DAPI (Invitrogen, Carlsbad, CA; D1306 diluted at 1:100 for 5 
minutes at RT) were used. Slides were coverslipped using Prolong Gold Antifade Mountant (P/N 
P36930). 
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For hypoxy region detection, mice were injected intravenously with 60 mg/kg of pimonidazole 
(Hypoxyprobe-1 Plus kit, HPI Inc., Burlington, MA) before sacrificing mice. Formalin fixed 
paraffin embedded samples where cut at 5uM and allowed to air dry. The slides were placed on 
the Leica Bond RX and stained using supplied primary and secondary antibodies. 
All slides that were bright field chromogenic IHC were scanned using the Aperio Scanscope XT 
system (Aperio Technologies, Inc., Vista, CA) at 20x resolution and the fluorescent scans were 
from the Aperio Scanscope FL (Aperio Technologies) at 20x resolution. 
 
Luciferase reporter gene assays 
The 3’UTR of DUSP3, 4, 6, and 19 and BIRC2 was amplified using specific primers 
(Supplementary File 1) and cloned downstream of luciferase gene into pcDNA6/Luc(30) using 
an In-Fusion HD cloning kit (Takara Bio USA, Inc., Mountain View, CA). The recombinant 
pcDNA6/LUC-DUSP (or pcDNA6/LUC-DUSP-211Δ), pcDNA4/MIR211(31), and pRL-CMV 
(a Renilla luciferase plasmid, Promega, Madison, WI) plasmids were transfected into HEK293T 
cells (Thermo Fisher Scientific) using FuGENE HD (Promega, Madison, WI). For BIRC2 
reporter assay, pcDNA6/LUC-BIRC2 or pcDNA6/LUC-BIRC2-211ΔΔ plasmids were used. At 
48 h post-transfection, both firefly and renilla luciferase activities were measured by the Dual-
Glo luciferase Assay (Promega) using a GloMax 20/20 Luminometer (Promega). Firefly 
luciferase activities were normalized with renilla luciferase activities.  
 
siRNA-mediated knockdown 
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siRNA targeting ERK5 (catalog no. 4427038, ID: s11149, and catalog no. 4427037, ID: s11150), 
DUSP3 (catalog no. 4427038, ID: s4371) DUSP4 (catalog no. 4427037, ID: s4372), DUSP6 
(catalog no. 4427037, ID: s4378), DUSP19 (catalog no. 4427038, ID: s44472) and BIRC2 
(catalog no. 4427038, ID: s1450) were purchased from Ambion (Foster City, CA). siRNAs were 
transfected at 20 nM for 48h using Lipofectamine RNAiMAX (Life Technologies, Carlsbad, 
CA). The efficiency was determined by qRT-PCR using TaqMan assay.  
 
2D and 3D cellular growth assays 
For growth inhibition assay by XMD8-92 (Selleckchem, Houston, TX), cells were seeded at a 
density of 4000 cells per well in a 96-well plate and compounds were added the next day. Cell 
viability was determined after 6 days. For growth inhibition assays with AX15836 (Tocris, 
Minneapolis, MN) in 2D culture systems, cells were seeded at a density of 1000 cells/well in 
384-well plates (3 biological replicates). Compounds were added subsequent to cell seeding and 
diluted twofold to create eighteen-point titrations. Control cells were treated with DMSO. Cell 
viability was assessed after 5 days by XTT Cell Proliferation Assay (Biotium, Fremont, CA) 
according to the manufacturer's instructions. 
For growth inhibition assays with AX15836 in 3D cell cultures, cells were seeded at a density of 
5000 cells/well in 96-well plates (3 biological replicates) in soft agar. Compounds were added 2 
days after cell seeding and diluted twofold to create eight-point titrations. Control cells were 
treated with dimethylsulfoxide (DMSO). Cell viability was assessed after 10 days by Alamar 
Blue Cell Proliferation Assay (Thermo Fisher Scientific) according to the manufacturer's 
instructions.  
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For growth inhibition assays with vemurafenib (PLX4032, Selleckchem, Houston, TX) in 2D 
cell cultures, cells were seeded at a density of 1000 cells/well in 384-well plates (3 biological 
replicates). Compound was added subsequent to cell seeding and diluted twofold to create an 
eighteen-point titration. Control cells were treated with DMSO. Cell viability was assessed after 
5 days by XTT Cell Proliferation Assay according to the manufacturer's instructions. 
 
Western blotting 
Whole cell extracts were fractionated by SDS-PAGE and transferred to a polyvinylidene 
difluoride membrane. After incubation with 5% bovine serum albumin (Catalog no. BP1600-
100, Fisher Scientific, Hampton, NH) in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% 
Tween 20) for 60 min, the membrane was washed with TBST and incubated with antibodies 
against phospho-ERK5 (EMD Millipore, catalog no. 07-507), ERK5 (Cell Signaling, catalog no. 
3552), phospho-ERK1/2 (Cell Signaling, catalog no. 4370), ERK1/2 (Cell Signaling, catalog no. 
4695), and GAPDH (Santa Cruz Biotechnology) at 4°C for overnight. Membranes were washed 
and incubated with a 1:5000 dilution of horseradish peroxidase-conjugated anti-mouse or anti-
rabbit antibodies for 1 h. Blots were washed and developed with the ECL system (Amersham 
Biosciences, Piscataway, NJ) according to the manufacturer’s protocols. 
 
RNA immunopurification (RIP) in A375/211 cells 
RIP assays in A375/211 cell extracts were performed as described previously (32,33). Briefly, 
cells were resuspended in lysis buffer (150 mM KCl, 25 mM Tris/Cl pH 7.4, 5 mM EDTA, 0.5% 
Nonidet P-40, 5 mM DTT, 1 mM PMSF, 1x protease inhibitor cocktail (Pierce, Thermo Fisher 
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Scientific), 100 U/ml SUPERaseIn (Ambion, Austin, TX)). Lysates were spun, and the 
supernatant was incubated with Dynal My1 streptavidin-coated magnetic beads (Invitrogen, 
Carlsbad, CA) coupled to biotinylated AGO-specific 4F9 antibody (Santa Cruz, catalog no. sc-
53521). The beads were washed twice with ice-cold lysis buffer and RNA was extracted with 
TRIzol and the miRNeasy RNA extraction kit (Qiagen, Valencia, CA) and stored at −80°C. 
 
RNA-Sequencing 
RIPed RNAs were subjected to double strand cDNA synthesis using an Ovation RNA-Seq 
System V2 (NuGen Technologies, Inc., San Carlos, CA). High-throughput sequencing libraries 
were constructed using the TruSeq ChIP Sample preparation kit (Illumina, San Diego, CA) and 
sequenced on a HiSeq 2500 (Illumina) with 50 bp read lengths. The enriched peaks were defined 
by MACS (43). For xenografts RNA-seq, total RNA was used for constructing libraries using the 
Illumina TruSeq Stranded Total RNA Library preparation kit (Illumina Inc). Single-end 50 base-
pair sequencing was performed on Illumina HiSeq 2500. 
 
Mouse xenografts 
Severe combined immunodeficiency (SCID) mice (five weeks old) were injected subcutaneously 
with 5.0 x 106 cells/site (n = 5 per group) into lower left flank. Tumor size was monitored with 
digital calipers and tumor volume in mm3 was calculated by the formula: volume = (width)2 x 
length/2. Mice were euthanized and weights and pictures of excised tumors were taken. 
 
RNA extraction and real-time quantitative reverse transcription-PCR (qRT-PCR) 
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Total RNA was purified using the Direct-zol RNA Miniprep kit (Zymo Research, Irvine, CA). 
For RNAs from xenografts, tumor tissues were pulverized and then used for purification. 
Quantitative PCR was carried out using TaqMan miRNA assays or SYBR Green mRNA assays 
as previously described(34). Primer sequences are listed in Supplementary File 1. 
 
Exosome purification and qRT-PCR 
Exosomes were purified using ExoCap™ Exosome Isolation and Enrichment Kits (MBL 
International Corp., Woburn, MA) according to manufacturer’s protocol. Briefly, cells were 
plated and after 24 h, media were replaced with media containing exosome-depleted fetal bovine 
serum (FBS; Thermo Fisher Scientific, Waltham, MA) for 48 h. The conditioned media were 
collected, spun, and filtered to remove cells. The filtered conditioned media were used for 
exosome purification. Nucleic acids were isolated from captured exosomes in 10 ul volume.  One 
ul out of 10 ul RNA was used for cDNA synthesis in a 15 ul reaction volume using a TaqMan™ 
MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific). qRT-PCR was performed in a 
20 ul reaction volume with 1 ul of cDNA. The cycle threshold (Ct) value was used to compare 
the levels of miRNAs. 
 
Targeted metabolomics analysis 
Targeted metabolomics of cells and xenografts was performed at the Cancer Metabolism Core at 
Sanford Burnham Prebys Medical Research Institute (SBPMRI; La Jolla, CA, USA) as 
previously described(35). Briefly, tumor samples (15-30 mg) were transferred to 2 ml round-
bottom tubes (Qiagen, Hilden, Germany) with the addition of a 5 mm stainless steel bead 
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(Qiagen) and ice-cold 50% methanol/20 µM L-norvaline (450 µl). Tubes were shaken at 
maximum speed (30) for 2 min (Qiagen Tissuelyser), vortexed, and placed on dry ice for 30 min. 
After thawing on ice, samples were centrifuged (15,000 x g, 10 min, 4°C). The supernatant was 
transferred to a new tube, vortexed with chloroform (220 µl), and centrifuged (15,000 x g, 15 
min, 4°C). The top layer was dried (MiVac, 4 h), derivatized, and analyzed by GC-MS to 
quantify small polar metabolites as previously described(35). 
 
Melanoma Cell lines 
Drug response sensitivities for vemurafenib in 39 melanoma cell lines have been described 
previously  a,b,c, and the area under the curve (AUC) data were utilized in Supplemental Table 6, 
to correlate MIR211 expression with vemurafenib responsiveness. 
a) Ding, K.-F., Finlay, D., Yin, H., Hendricks, W.P.D., Sereduk, C., Kiefer, J., Sekulic, A., 
LoRusso, P.M., Vuori, K., Trent, J.M. and Schork, N.J. (2017) Analysis of Variability in High 
Throughput Screening Data Applications to Melanoma Cell Lines and Drug Responses. 
Oncotarget 8:27786-27799. doi: 10.18632/oncotarget.15347 
b) Ding, K.-F., Petricoin III, E., Finlay, D., Yin, H., Hendricks, W.P.D., Sereduk, C., Kiefer, J., 
Sekulic, A., LoRusso, P.M., Vuori, K., Trent, J.M. and Schork, N.J. (2017) Nonlinear Mixed 
Effects Dose Response Modeling in High Throughput Drug Screens: Application to Melanoma 
Cell Analysis. Oncotarget 9:5044-5057. doi: 10.18632/oncotarget.23495 
c) Ding, K.-F., Finlay, D., Yin, H., Hendricks, W.P.D., Sereduk, C., Kiefer, J., Sekulic, A., 
LoRusso, P.M., Vuori, K., Trent, J.M. and Schork, N.J. (2018) Network Rewiring in Cancer: 
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Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients. Front. Genet. 
9:228. doi: 10.3389/fgene.2018.00228 
 
Prediction of putative MIR211 targets 
microRNA.org (http://www.microrna.org) and miRDB (http://www.mirdb.org) were used for 
target gene prediction as previously described (36,37). Targets overlapping between the two web 
sites were selected. 
 
Ingenuity pathway analysis (IPA) 
To analyze pathways affected by MIR211, differentially expressed genes between A375 and 
A375/211 xenografts were compiled and analyzed using Qiagen’s IPA. Analysis was conducted 
via the IPA web portal (www.ingenuity.com).  
 
RESULTS AND DISCUSSION 
Ectopic MIR211 expression promotes in vivo tumor growth  
The amelanotic melanoma cell line A375, which has a constitutively activated MAPK pathway 
due to BRAFV600E mutation and low basal MIR211 expression, and their stable MIR211-
overexpressing counterparts A375/211 cells (Supplementary Fig. S1), were injected 
subcutaneously into the flanks of severe combined immunodeficiency (SCID) mice. Ectopic 
MIR211 expression significantly and rapidly increased aggressive tumor growth and weight 
(Fig. 1A-C), with rapid growth of A375/211 tumors from day six to approximately eight-times 
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the volume of their parental controls by day 12, when mice were sacrificed due to tumor burden. 
An additional two independent stable clones (A375/211-c2 and A375/211-c3) behaved similarly 
(Supplementary Fig. S2), excluding a clonal effect. A negative control MIR210 (known as a 
hypoxia inducible miRNA and also the fine-tuner of the hypoxic response(38) did not affect 
tumor growth when overexpressed in A375 (A375/210) cells (Supplementary Fig. S3A-C). 
Further, to investigate whether the effect of MIR211 might be specific to A375 cells, we 
ectopically expressed MIR211 in another amelanotic melanoma cell line, LOX-IMV1 (LOX-
IMV1/211), which also harbors a BRAFV600E mutation(39). Again, there was a significant 
increase in tumor size and weight relative to the vector only control cell line in vivo 
(Supplementary Fig. S4). 
 
Figure 1. MIR211 promotes tumor growth and the cancer phenotype in vivo. A. A375 amelanotic melanoma 
cells and their MIR211 (A375/211) overexpressing counterparts were injected subcutaneously into the flanks of 
SCID mice and tumor volume measured with electronic calipers until termination of the experiment at 12 days. 
A375/211 tumors were significantly larger and grew more rapidly than the other tumors. B. Tumors were excised 
and weighed at the termination of the experiment on day 12. MIR211-overexpressing tumors were significantly 
heavier than either parental A375 xenografts. Student t-test, *** p ≤ 0.001. C. Photographs of subcutaneous tumor 
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xenografts at the termination of the experiment at day 12. A375/211 xenografts were large and began to ulcerate 
while tumors in the other groups were barely visible. D. Photomicrographs of A375 and A375/211 xenografts 
showing tumor morphology (H&E; scale bar 500 um); increased proliferation in A375/211 xenografts (Ki67 IHC; 
scale bar 100 um); increased blood vessel density in A375/211 xenografts (CD31 IF; scale bar 100 um); increased 
areas of hypoxia in A375/211 xenografts (hypoxyprobe; scale bar 100 um); and decreased PDK4 expression in 
A375/211 xenografts (PDK4 IHC; scale bar 500 um). 
Cell proliferation was examined in xenograft tissues using antibodies targeting Ki67, a pan-cell 
cycle marker. Approximately 30% of A375 cells showed strong nuclear Ki67 expression 
compared to 100% of A375/211 cells (Fig. 1D), consistent with the observation that A375/211 
cells divide more rapidly than parental A375 cells. CD31 immunofluorescence (IF) to assess 
blood vessel density revealed that angiogenesis was markedly enhanced in A375/211 tumors 
compared to A375 tumors (Fig. 1D). Using pimonidazole (Hypoxyprobe TM) to evaluate tumor 
hypoxia(40), A375/211 xenografts contained more hypoxic areas compared to A375 xenografts, 
suggesting that A375/211 tumors rapidly outgrew their blood supplies even with enhanced 
angiogenesis (Fig. 1D).  We previously established a link between MIR211 and 
metabolism(16,41). MIR211 overexpression increases mitochondrial respiration by targeting 
pyruvate dehydrogenase kinase 4 (PDK4)(16), which generates mitochondrial acetyl-coA and 
proliferative dependence on the TCA cycle and oxidative phosphorylation(16). Consistent with 
these previous findings, PDK4 expression was reduced in A375/211 cells, both at the transcript 
(Supplementary Fig. S5A) and protein levels (Fig. 1D). To examine whether restoring PDK4 in 
A375/211 cells overcame the effects of MIR211 overexpression, stable A375/211/PDK4-re-
expressing cells with similar PDK4 expression to parental A375 cells (Supplementary Fig. 
S5B) were injected into SCID mice. As expected, PDK4 activity reversed the phenotype, 
reducing tumor growth to below that of the parental A375 xenografts (Supplementary Fig. 
S5C). Ectopic expression of PDK4 alone in A375 cells was sufficient to rescue the aggressive 
phenotype in A375/211 and A375 tumors (Supplementary Fig. S6A-C). Interestingly, 
A375/PDK4 xenografts were not large until day 73 (data not shown).   
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Human MIR211 in tumor xenografts modulates mouse gene expression 
The oncogenic effects of MIR211 in vivo are paradoxical to the tumor-suppressing effects seen 
in vitro(15). To resolve this paradox, we reasoned that this may be caused by an altered tumor 
microenvironment as MIR211 in xenografts might either directly or indirectly interact with the 
host (murine) cells. This model has three essential postulates: (1) a human-specific signal is 
emitted by the implanted human cells; (2) mouse cells respond to the human-specific signal; (3) 
human cells in turn respond to mouse-specific feedback signals. Since exosomes mediate 
intercellular communication in tissues and contain miRNAs(42) (including MIR211(43)), we 
hypothesized that MIR211 might be delivered to adjacent mouse cells in the tumor 
microenvironment, and thereby satisfies the first condition of the model.  
To test this hypothesis, A375 and A375/211 cells were grown with exosome-free fetal bovine 
serum, conditioned media collected, and MIR211, MIR16, and MIR23a (the latter two as 
positive controls(44,45)) levels analyzed by qRT-PCR. The expression levels of MIR16 and 
MIR23a were similar in the cellular and exosomal fractions of A375 or A375/211 cell lines 
(Supplementary Fig. S7A & B). By contrast, as anticipated by the model, MIR211 levels were 
enriched approximately 100-fold in A375/211 cell-free medium (Fig. 2A) and approximately 
1300-fold in A375/211 exosomes compared to the parental A375 line (Fig. 2B).  
We now examine the second postulate of the model, in which mouse cells are assumed to 
respond to the human cells. Since RNA-seq can accurately differentiate human and mouse 
transcripts in xenografts(46), we next performed RNA-seq of total RNA from xenografts to 
examine whether the human tumor cells affected the mouse transcriptome. First, reads were 
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separately aligned to the human (GRCH37/hg19) and mouse (GRCm/mm10) genomes, after 
which only mouse transcriptome changes were assessed by Ingenuity Pathway Analysis (IPA) to 
identify the effect of human cells on the mouse transcriptome. IPA analysis revealed a number of 
activated pathways including cell cycle, growth, proliferation, movement, and cardiovascular 
system development and function (Supplementary Table S1). Next, the same sequencing data 
were subjected to Gene Set Enrichment Analysis (GSEA), which revealed enrichment of gene 
expression related to hypoxia response, angiogenesis and endothelial cell pathways in the mouse 
transcriptome (Supplementary Fig. S8), consistent with the increased CD31 endothelial staining 
seen in A375/211 xenografts between cell junctions (Fig. 1D). 
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Figure 2. Cell-free (A) and exosome-loaded (B) MIR211 in A375/211 cells. A and B. MIR211 levels were 
measured in A375/211 cell free media (A) and exosomes (B) in culture and compared to parental cells. qRT-PCR 
results demonstrate elevated levels of MIR211 in both cell free media and exosomes. C. Heatmap for 56 putative 
MIR211 mouse targets showing downregulation in A375/211 xenografts. 
We next analyzed the expression levels of putative MIR211 targets in mouse RNA-seq data. 
Human and mouse MIR211 sequences differ by only a single nucleotide towards the 3’ end 
(Supplementary Fig. S7C), so their targets are likely to be similar; indeed, using an miRNA 
target prediction algorithm(37), human and mouse MIR211 had the same predicted targets (data 
not shown). Among 481 putative targets common to both target prediction algorithms 
(microRNA.org(36) and miRDB(37)), 56 mouse genes were significantly downregulated (Fig. 
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2C and Supplementary Table S2, log2 fold change ≤ -1.0, p < 0.05) including Angpt1, which is 
often decreased in cancer and associated with increased vasculogenesis in renal cell 
carcinoma(47). Similar to our results, Dror et al. recently reported that MIR211 is transferred to 
fibroblasts through melanosomes to promote a cancer-associated fibroblast phenotype(11). 
Taken together, these results support the possibility that MIR211 is transferred to adjacent mouse 
endothelial cells via exosomes to participate in altering the cellular properties of mouse cells to 
those previously associated with various cancers. 
 
Transcriptomic changes in xenografted human cells within the tumor microenvironment 
Explicit testing of the feedback effects of murine cells on the human tumor cells is difficult in the 
absence of an identified feedback effector molecule. We therefore used an indirect measure and 
investigated whether MIR211 expression in xenografts causes changes in the human-specific 
transcriptome relative to that in the culture tumor cells that are sufficient to explain rapid tumor 
growth phenotype. 
A375, A375/211, and A375/211/PDK4 xenografts were subjected to RNA-seq and human-
specific transcriptomes were analyzed (Supplementary Table S3 and Supplementary Fig. S9). The 
results were consistent with the activation of four human-specific pathways (cyclins and cell 
cycle regulation, ERK5 signaling, hypoxia signaling, and telomerase signaling; z-score ≥ 2.0) 
and the inactivation of five human-specific pathways (cAMP-mediated signaling, interferon 
signaling, PPARα/RXRα activation, Gαi signaling, and Gαq signaling; z-score ≤ -2.0) in tumors 
expressing the human-specific MIR211. These results were not previously observed in A375 
cells or A375/211 cells grown in vitro cultures (30). 
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To determine whether upregulated genes in different xenografts (log2 fold change ≥ 1.0, p ≤ 
0.05) shared common biological functions, we performed GSEA(48) on the human-specific 
upregulated transcripts. Epithelial-to-mesenchymal transition (EMT) was the most significantly 
enriched gene set (Supplementary Table S4, FDR = 4.87 x 10-27). In addition, MIR211 altered 
several EMT-related pathways including estrogen response genes (early (FDR = 1.52 x 10-2) and 
late (FDR = 8.33 x 10-4)), genes upregulated in hypoxia (FDR = 4.09E x 10-23), and genes 
responding to ultraviolet (UV) radiation (up (FDR = 2.15E x 10-4) and down (FDR = 2.41 x 10-
6))(49,50). Several lipid metabolism-related gene sets including cholesterol homeostasis, 
adipogenesis, and fatty acid metabolism were also upregulated (FDR = 2.54 x 10-6, 1.63 x 10-4, 
and 2.15 x 10-4, respectively).  
 
MIR211 directly targets negative regulators of the ERK5 pathway 
Four human-specific signaling pathways were activated in A375/211 compared to A375 
xenografts (Supplementary Table S3 and Supplementary Fig. S9) including the ERK5 
signaling axis. ERK5 itself was recently shown to be activated in melanomas(51), and we 
reasoned that negative regulators of the ERK5 pathway could be MIR211 targets. Using 
TargetScan(52), microRNA.org(36), and miRDB(37), we identified putative MIR211 targets in 
the ERK5 signaling pathway, which included baculoviral IAP repeat containing 2 (BIRC2) and 
several dual specificity phosphatases (DUSPs) including DUSP3, DUSP4, DUSP6, and 
DUSP19. BIRC2 is an ubiquitin ligase and its family member, BIRC4, is a known regulator of 
MEKK2, which lies upstream of MAPK kinase kinase in the ERK5 pathway(53). DUSP proteins 
are possible phosphatases of ERK5 signaling proteins, which are expected to inhibit ERK5 
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signaling activation (Supplementary Fig. S10), and DUSP4 was previously predicted as an 
MIR211 target gene in melanoma(54).  
In an attempt to determine which candidates were directly regulated by MIR211 in vivo, we next 
directly determined human-specific MIR211 targets using Argonaute-2 (Ago2) 
immunopurification, with co-immunopurified RNAs determined by RNA-seq. To validate the 
RIP-seq results, bound RNAs were filtered by MIR211-binding sites to identify putative MIR211 
targets. Both BIRC2 and DUSP family members were enriched by Ago2 immunopurification 
(Supplementary Table S5). 
We next performed an miRNA target cleavage assay (luciferase reporter assay) to further 
confirm that DUSP6 (Fig. 3A) and BIRC2, DUSP4, and DUSP19 are direct MIR211 targets 
(Supplementary Fig. S11A). When reporter plasmids were co-transfected with plasmids 
expressing MIR211 into HEK-293T cells, the wild-type DUSP6 reporter showed reduced 
luciferase activity, while the mutant one did not (Fig. 3A). Further, when a reporter carrying 
luciferase with the 3’UTR of DUSP6 was transiently transfected to A375 or A375/211 cells, a 
reduction in luciferase activity was observed in A375/211 cells compared to A375 cells (Fig. 
3B). To determine which DUSPs specifically dephosphorylate ERK5, A375 cells were treated 
with siRNAs against DUSP3, DUSP4, DUSP6, and DUSP19, and ERK5 phosphorylation was 
assessed. As shown in Supplementary Fig. S11B, knockdown of each DUSP except DUSP3 
increased ERK5 phosphorylation. Furthermore, when DUSP proteins were ectopically expressed 
in A375/211 cells, DUSP6 rapidly decreased ERK5 phosphorylation, indicating DUSP6 may act 
rapidly and specifically on ERK5 (Fig. 3C and Supplementary Fig. S11C). DUSP6 protein 
level was lower in A375/211 cells and corresponded to higher ERK5 phosphorylation than in 
A375 cells (Fig. 3D). Next we engineered a cell line to re-express DUSP6 in A375/211 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/548818doi: bioRxiv preprint first posted online Feb. 13, 2019; 
 21
background and cells were injected subcutaneously into the flanks of SCID mice together with 
cells from A375 and A375/211 as controls. The re-expression of DUSP6 significantly reduced 
A375/211 tumor growth (Fig. 3E), and DUSP6-overexpressing tumors were significantly smaller 
compared to A375/211 xenografts harvested the same day (Fig. 3F; p ≤ 0.001). Given these 
results, we further investigated the role of DUSP6 and ERK5 axes in melanoma. 
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Figure 3. MIR211 targets negative regulators of ERK5 pathway. A. Luciferase reporter assays carrying either 
wild-type 3’UTR or a mutant with several nucleotides swapped in the region corresponding to the MIR211 seed. 
When reporter plasmids were co-transfected with plasmids expressing MIR211 into HEK-293T cells, the wild-type 
DUSP6 reporter showed reduced luciferase activity, while the mutant one did not. Student t-test, ns: not significant, 
*** p ≤ 0.001. B. Reporter carrying luciferase with 3’UTR of DUSP6 was transiently transfected to A375 or 
A375/211 cells. A reduction in luciferase activity was observed in A375/211 cells compared to A375 cells. Student 
t-test, **** p ≤ 0.0001. C. Western blot showing the decrease of phospho-ERK5 (pERK5) upon overexpression of 
DUSP6. D. Western blot analysis of pERK5 and DUSP6 in A375 and A375/211 cells E. A375, A375/211, and 
A375/211/DUSP6 cells were injected subcutaneously into the flanks of SCID mice and tumor volume measured 
with electronic calipers until termination of the experiment at 14 days. The ectopic expression of DUSP6 reduced 
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significantly A375/211 tumor growth. F. Tumors were excised and weighed at the termination of the experiment at 
14 days. DUSP6-overexpressing tumors were significantly lighter than A375/211 xenografts. Student t-test, *** p ≤ 
0.001. 
 
ERK5 pathway activation by MIR211 confers melanoma drug resistance 
To determine if DUSP6 affects ERK1/2, we analyzed ERK1/2 phosphorylation upon DUSP6 
siRNA knockdown (Fig. 4A, Supplementary Fig. S12); ERK1/2 phosphorylation was not 
affected by DUSP6 knockdown (Fig. 4A). 
 
Figure 4. MIR211 activates the ERK5 pathway via DUSP6. A. Western blots of A375 and A375/211 cells treated 
with siDUSP6 or PD0325901 (100 nM), a MEK1/2 inhibitor. Phospho-ERK5 (pERK5) was lower in A375 cells 
than A375/211 cells and increased upon siDUSP6 treatment in both cell types. ERK1/2 phosphorylation was not 
affected by DUSP6 knockdown. PD0325901 efficiently abrogated ERK1/2 phosphorylation and slightly 
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increased ERK5 phosphorylation. B. Cell viability assays showing that A375/211 cells were more sensitive to 
the ERK5 inhibitor XMD8-92, suggesting that A375/211 cells are more dependent on the ERK5 pathway. C. 
IC50 concentration of XMD8-92 for A375 and A375/211 cells. XMD8-92 IC50 value of A375/211 cells was about 
two folds lower than that of A375. D. IC50 concentration of AX15836 for A375/211 cells in two and three 
dimensional culture. In 3D culture, A375/211 cells were much sensitive than 2D culture to AX15836, while A375 
and A375/211 cells showed similar sensitivity to AX15836 in 2D culture. 
Phospho-ERK5 (pERK5) was lower in A375 cells than in A375/211 cells and increased upon 
siDUSP6 treatment in both cell lines (Fig. 4A). As expected, stable overexpression of DUSP6 
decreased phospho-ERK5 levels (Fig. 3C). ERK5 is activated upon ERK1/2 inhibition in 
intestinal epithelial cells and colorectal cancer cell lines(55). To establish whether ERK5 is 
also activated by ERK1/2 pathway inhibition in melanoma, A375 and A375/211 cells were 
treated with PD0325901, which inhibits the ERK1/2 kinase MEK1/2. PD0325901 efficiently 
abrogated ERK1/2 phosphorylation and slightly increased ERK5 phosphorylation (Fig. 4A). 
Since the ERK5 pathway was activated in A375/211 cells due to DUSP6 inhibition by 
MIR211, we hypothesized that the ERK5 pathway may compensate for loss of ERK1/2 
signaling to drive hyperproliferation in melanomas. Consistent with this, A375/211 cells were 
more sensitive to the ERK5 inhibitor XMD8-92 than parental cells (Fig. 4B & 4C). XMD8-
82, the first generation ERK5 inhibitor, has been reported to have off-target activity on 
bromodomains(56), so we examined the effect of AX15836, an XMD8-92 derivative with no 
significant off-target activity(56) on A375/211 cell proliferation. While AX15836 had no anti-
proliferative effect on two-dimensional cultures over a short period (48 h), when cells were 
grown in 3-D cultures (colony forming assay), the IC50 of AX15836 on A375/211 cells was 
reduced from 62 uM to 6.7 uM, indicating that A375/211 cells were more sensitive to drug 
than A375 cells (Fig. 4D). Further, A375/211 cell growth was inhibited by ERK5 siRNA 
knockdown (Supplementary Fig. S13B).  
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Finally, MIR211 expression increases in melanomas treated with the BRAF inhibitor 
vemurafenib and may contribute to vemurafenib resistance(27,28,43). MIR211 levels were 
similarly increased in A375 cells treated with vemurafenib (Fig. 5A) and the MEK inhibitor 
cobimetinib (Fig. 5B). In addition, ectopic MIR211 expression increased vemurafenib 
resistance 10.4-fold compared to A375 cells (Fig. 5C). To examine whether vemurafenib 
resistance may be mediated via the MIR211-ERK5 axis, pERK5 levels were evaluated in 
vemurafenib-resistant cell lines (Fig. 5D), previously thought to become resistant primarily 
due to ERK1/2 pathway reactivation(27). Indeed, while ERK1/2 phosphorylation was 
significantly increased in resistant cell lines compared to parental A375 cells, ERK5 
phosphorylation also increased, suggesting that ERK5 signaling might also contribute to 
acquired drug resistance in melanoma. In agreement with this hypothesis, MIR211 expression 
was also significantly increased in these cell lines (Fig. 5E). To further investigate these 
observations, MIR211 gene expression was quantified in 39 melanoma cell lines 
(Supplementary Table S6). Interestingly, MIR211 expression (low and high) and 
vemurafenib resistance partitioned melanoma cell lines into two groups (Supplementary Fig. 
S14). Vemurafenib resistance and MIR211 expression were correlated in the MIR211 low but 
not the MIR211-high group (Fig. 5F).  
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Figure 5. MIR211 contributes to vemurafenib resistance via ERK5. A. MIR211 expression levels increased in 
A375 cells treated with vemurafenib. B. MIR211 levels increased in A375 cells treated with MEK1 inhibitor, 
cobimetinib. C. Cell viability assays showing that ectopic MIR211 expression increased vemurafenib resistance 
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by 10.4-fold compared to A375 cells. D. Both ERK1/2 and ERK5 phosphorylation increase markedly and 
significantly in four clones of A375 cells with acquired vemurafenib resistance. E. MIR211 levels increased in 
vemurafenib resistant cell lines compared to A375 cells. F. Vermurafenib resistance and MIR211 levels were 
correlated in melanoma cell lines with low expression level of MIR211. (Pearson r = 0.5781, 95% confidence 
interval = 0.207 to 0.8038, R2 = 0.3343, p = 0.0048). 
 
In vivo tumor growth induced by MIR211 is not fully explained by metabolic changes 
PDK inhibits pyruvate dehydrogenase(57) and, in cancer, PDK shunts glucose from TCA cycle 
to produce lactate(58). We previously showed that inhibition of PDK4 by MIR211 
overexpression in A375 cells in vitro increased the oxygen consumption rate (OCR), indicating 
enhanced mitochondrial activity(16). To determine whether PDK4 regulation affects tumor 
growth by modulating metabolism and whether this effect persists in vivo, we performed targeted 
metabolite analysis (Supplementary Fig. S15A). Metabolites were extracted from A375, 
A375/211, or A375/211/PDK xenografts, derivatized (described above), and analyzed by mass 
spectrometry.  
MIR211 overexpression did not significantly affect glycolysis intermediates, although ectopic 
PDK4 expression significantly decreased lactate production (Supplementary Fig. S15B). 
Similarly, TCA cycle intermediates were generally unaffected except for succinate (reduced by 
PDK4 –re-expression) and fumarate (decreased by MIR211 overexpression but partially restored 
in A374/211/PDK4 xenografts) (Supplementary Fig. S15C). Amino acid levels were almost 
uniformly decreased in A375/211 xenografts and partially restored in A375/211/PDK4 
xenografts except for threonine, which further decreased with the addition of PDK4 
(Supplementary Fig. S15D). Overall, although MIR211 acts as a metabolic switch in vitro(16) 
and in that context might dictate the cellular phenotype, MIR211’s effects on metabolic 
pathways appear to be largely “buffered” within the physiological environment in vivo. It is still 
possible that human-specific exosomal MIR211 does switch murine cell metabolism (Warburg 
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effects), seen previously in cultured cells(30), and the feedback effects by the mouse cells 
prevent this metabolic switch to be actuated in the human cells. 
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In conclusion, these results suggest that MIR211 has pleiotropic effects in vitro and in vivo. 
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While MIR211 appears to render melanoma cells metabolically vulnerable in vitro, these effects 
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appear to be largely buffered in vivo, instead upregulating critical cancer pathways including
ERK5 signaling to regulate the cell cycle and angiogenesis, with therapeutic consequences. Our
results are summarized in the model we propose in Figure 6. As we proposed earlier, a human-
specific signal is released with MIR211 from the implanted human cells via exosome to mouse
cells in turn respond to mouse-specific feedback signals. Melanoma cells appear to adapt their
microenvironment and adapt to their microenvironment to gain a growth advantage, especially
when drugs apply selection pressure. It remains to be determined what factors dictate which
pathways are targeted by miRNAs at any given point in time, but future precision therapies based
on MIR211 or its target pathways are likely to require consideration of this exquisite context-
dependency.  
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Figure 6. A model summarizing the interaction between A375/211 and the tumor microenvironment. Human 
tumor cells (yellow) expressing MIR211, secrete exosomes (red ellipses) loaded with MIR211, which enter mouse 
cells (purple). In mouse cells, MIR211 inhibits its murine targets, which in turn activate the transcription of a 
number genes including ANGPTL2, EFEMP2, CD74, POSTN, C1QTNF3, and COL5A1. These changes in murine 
cells stimulate angiogenesis and cause feedback to the human cells, interacting with the MIR211 circuit involving 
DUSP6, to induce ERK5 signaling, resulting in tumor hyper-proliferation. While MIR211’s target PDK4 is inhibited 
within human cells, which can be rescued by over-expressing the PDK4 cDNA. 
  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/548818doi: bioRxiv preprint first posted online Feb. 13, 2019; 
 33
ACCESSION NUMBERS 
All xenografts RNA-seq and Ago2 RIP-seq datasets have been deposited with Gene Expression 
Omnibus (GEO) under accession number GSE125836. 
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